The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-ß? agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
 
Iphigenie Korakis
Honoraria - MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Anaveon (Inst); Astellas Pharma (Inst); C4 Therapeutics (Inst); DAIICHI Sankyo (Inst); Dragonfly Therapeutics (Inst); Fore Biotherapeutics (Inst); Gilead Sciences (Inst); ImCheck therapeutics (Inst); Immunocore (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - Roche
 
Martina Imbimbo
Speakers' Bureau - Bristol-Myers Squibb (Inst)
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; immunocore; Janssen Oncology; Merck Serono; MSD
Consulting or Advisory Role - Immatics; immunocore; Janssen-Cilag; MSD; Pfizer
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Janssen Oncology; Merck Serono; Pfizer
Other Relationship - Ipsen
 
Ignacio Ortego
Travel, Accommodations, Expenses - Janssen Oncology; Roche
 
Pascale Tomasini
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Daiichi Sankyo Europe GmbH; Janssen; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Daiichi Sankyo Europe GmbH; Takeda
 
Kaïssa Ouali
Consulting or Advisory Role - Amgen; Anaveon; Sotio
Travel, Accommodations, Expenses - Amgen; Eisai; Sotio
 
Alexander Desuki
Honoraria - OnkoZert
Consulting or Advisory Role - Johnson & Johnson/Janssen; Lilly; MSD Oncology; Roche; SERVIER; SERVIER
Travel, Accommodations, Expenses - Merck Serono
 
Daniela Di Blasi
No Relationships to Disclose
 
Eduard Gasal
Employment - Innovent Biologics; Novartis
Leadership - Innovent Biologics
Stock and Other Ownership Interests - Amgen; Innovent Biologics; Natera; Novartis; Revolution Medicines
Travel, Accommodations, Expenses - Innovent Biologics; Novartis
 
Markus Joerger
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Roche (Inst)
Research Funding - Anaveon (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Immunophotonics (Inst); Incyte (Inst); Innomedica (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche; Sanofi